PRIMA-1 increases cisplatin sensitivity in chemoresistant ovarian cancer cells with p53 mutation: A requirement for Akt down-regulation

Journal of Ovarian Research

Volumn 6, Issue 1, 2013, Pages

  Kobayashi, Noriko ^a,b   Abedini, Mohammadreza ^a,c   Sakuragi, Noriaki ^b   Tsang, Benjamin K ^a,d  

^a OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^b HOKKAIDO UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c BIRJAND UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d Seoul National University   (South Korea)

Author keywords

Akt; Chemoresistance; Cisplatin; Ovarian cancer; p53; PRIMA 1

Indexed keywords

CISPLATIN; PROTEIN KINASE B; PROTEIN P53;

APOPTOSIS; ARTICLE; CANCER CELL; CANCER RESISTANCE; CONTROLLED STUDY; DRUG SENSITIVITY; FEMALE; GENE MUTATION; HUMAN; HUMAN CELL; OVARY CANCER; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR DOWN REGULATION;

EID: 84872760450     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-6-7     Document Type: Article

References (43)

1. Akt promotes cisplatin resistance in human ovarian cancer cells through inhibition of p53 phosphorylation and nuclear function. Fraser M, Bai T, Tsang BK, Int J Cancer 2008 122 534 546 10.1002/ijc.23086 17918180 (Pubitemid 350308944)
2. p53 is a determinant of X-linked inhibitor of apoptosis protein/Akt-mediated chemoresistance in human ovarian cancer cells. Fraser M, Leung BM, Yan X, Dan HC, Cheng JQ, Tsang BK, Cancer Res 2003 63 7081 7088 14612499 (Pubitemid 37413443)
3. Akt promotes chemoresistance in human ovarian cancer cells by modulating cisplatin-induced, p53-dependent ubiquitination of FLICE-like inhibitory protein. Abedini MR, Muller EJ, Bergeron R, Gray DA, Tsang BK, Oncogene 2010 29 11 25 10.1038/onc.2009.300 19802016
4. Cisplatin induces p53-dependent FLICE-like inhibitory protein ubiquitination in ovarian cancer cells. Abedini MR, Muller EJ, Brun J, Bergeron R, Gray DA, Tsang BK, Cancer Res 2008 68 4511 4517 10.1158/0008-5472.CAN-08-0673 18559494
5. Akt-mediated cisplatin resistance in ovarian cancer: modulation of p53 action on caspase-dependent mitochondrial death pathway. Yang X, Fraser M, Moll UM, Basak A, Tsang BK, Cancer Res 2006 66 3126 3136 10.1158/0008-5472.CAN-05- 0425 16540663
6. Induction of chemosensitivity in human lung cancer cells in vivo by adenovirus-mediated transfer of the wild-type p53 gene. Fujiwara T, Grimm EA, Mukhopadhyay T, Zhang WW, Owen-Schaub LB, Roth JA, Cancer Res 1994 54 2287 2291 8162565 (Pubitemid 24138709)
7. Aberrant p53 expression predicts clinical resistance to cisplatin-based chemotherapy in locally advanced non-small cell lung cancer. Rusch V, Klimstra D, Venkatraman E, Oliver J, Martini N, Gralla R, Cancer Res 1995 55 5038 5042 7585548
8. The IARC TP53 database: new online mutation analysis and recommendations to users. Olivier M, Eeles R, Hollstein M, Khan MA, Harris CC, Hainaut P, Hum Mutat 2002 19 607 614 10.1002/humu.10081 12007217 (Pubitemid 34556481)
9. PI3K/Akt and apoptosis: size matters. Franke TF, Hornik CP, Segev L, Shostak GA, Sugimoto C, Oncogene 2003 22 8983 8998 10.1038/sj.onc.1207115 14663477 (Pubitemid 38121699)
10. PI3K/Akt signalling pathway and cancer. Fresno Vara JA, Casado E, de Castro J, Cejas P, Belda-Iniesta C, Gonzalez-Baron M, Cancer Treat Rev 2004 30 193 204 10.1016/j.ctrv.2003.07.007 15023437 (Pubitemid 38418057)
11. Akt phosphorylation and stabilization of X-linked inhibitor of apoptosis protein (XIAP). Dan HC, Sun M, Kaneko S, Feldman RI, Nicosia SV, Wang HG, J Biol Chem 2004 279 5405 5412 14645242 (Pubitemid 38220563)
12. PRIMA-1(MET) synergizes with cisplatin to induce tumor cell apoptosis. Bykov VJ, Zache N, Stridh H, Westman J, Bergman J, Selivanova G, Oncogene 2005 24 3484 3491 10.1038/sj.onc.1208419 15735745 (Pubitemid 40756249)
13. Mutant p53-dependent growth suppression distinguishes PRIMA-1 from known anticancer drugs: a statistical analysis of information in the National Cancer Institute database. Bykov VJ, Issaeva N, Selivanova G, Wiman KG, Carcinogenesis 2002 23 2011 2018 10.1093/carcin/23.12.2011 12507923 (Pubitemid 36104953)
14. Restoration of the tumor suppressor function to mutant p53 by a low-molecular-weight compound. Bykov VJ, Issaeva N, Shilov A, Hultcrantz M, Pugacheva E, Chumakov P, Nat Med 2002 8 282 288 10.1038/nm0302-282 11875500 (Pubitemid 34250107)
15. Possible role of FLICE-like inhibitory protein (FLIP) in chemoresistant ovarian cancer cells in vitro. Abedini MR, Qiu Q, Yan X, Tsang BK, Oncogene 2004 23 6997 7004 10.1038/sj.onc.1207925 15258564 (Pubitemid 39319162)
16. Down-regulation of X-linked inhibitor of apoptosis protein induces apoptosis in chemoresistant human ovarian cancer cells. Sasaki H, Sheng Y, Kotsuji F, Tsang BK, Cancer Res 2000 60 5659 5666 11059757
17. The oncogenic phosphatase PPM1D confers cisplatin resistance in ovarian carcinoma cells by attenuating checkpoint kinase 1 and p53 activation. Ali AY, Abedini MR, Tsang BK, Oncogene 2012 31 2175 86 10.1038/onc.2011.399 21927021
18. A review of p53 expression and mutation in human benign, low malignant potential, and invasive epithelial ovarian tumors. Kmet LM, Cook LS, Magliocco AM, Cancer 2003 97 389 404 10.1002/cncr.11064 12518363 (Pubitemid 36133806)
19. PRIMA-1 synergizes with adriamycin to induce cell death in non-small cell lung cancer cells. Magrini R, Russo D, Ottaggio L, Fronza G, Inga A, Menichini P, J Cell Biochem 2008 104 2363 2373 10.1002/jcb.21794 18442053
20. Effects of PRIMA-1 on chronic lymphocytic leukaemia cells with and without hemizygous p53 deletion. Nahi H, Lehmann S, Mollgard L, Bengtzen S, Selivanova G, Wiman KG, Br J Haematol 2004 127 285 291 10.1111/j.1365-2141.2004. 05210.x 15491287 (Pubitemid 39468941)
21. PRIMA-1 induces apoptosis in acute myeloid leukaemia cells with p53 gene deletion. Nahi H, Merup M, Lehmann S, Bengtzen S, Mollgard L, Selivanova G, Br J Haematol 2006 132 230 236 10.1111/j.1365-2141.2005.05851.x 16398657 (Pubitemid 43381557)
22. Cancer. p53, guardian of the genome. Lane DP, Nature 1992 358 15 16 10.1038/358015a0 1614522
23. Re-activation of the p53 pathway inhibits in vivo and in vitro growth of hormone-dependent human breast cancer cells. Liang Y, Besch-Williford C, Benakanakere I, Hyder SM, Int J Oncol 2007 31 777 784 17786308
24. PRIMA-1 inhibits growth of breast cancer cells by re-activating mutant p53 protein. Liang Y, Besch-Williford C, Hyder SM, Int J Oncol 2009 35 1015 1023 19787255
25. PRIMA-1MET induces mitochondrial apoptosis through activation of caspase-2. Shen J, Vakifahmetoglu H, Stridh H, Zhivotovsky B, Wiman KG, Oncogene 2008 27 6571 6580 10.1038/onc.2008.249 18663359
26. Coping with stress: multiple ways to activate p53. Horn HF, Vousden KH, Oncogene 2007 26 1306 1316 10.1038/sj.onc.1210263 17322916 (Pubitemid 46328472)
27. Surfing the p53 network. Vogelstein B, Lane D, Levine AJ, Nature 2000 408 307 310 10.1038/35042675 11099028
28. Proteomic identification of heat shock protein 90 as a candidate target for p53 mutation reactivation by PRIMA-1 in breast cancer cells. Rehman A, Chahal MS, Tang X, Bruce JE, Pommier Y, Daoud SS, Breast Cancer Res 2005 7 765 774 10.1186/bcr1290
29. PRIMA-1 induces apoptosis by inhibiting JNK signaling but promoting the activation of Bax. Wang T, Lee K, Rehman A, Daoud SS, Biochem Biophys Res Commun 2007 352 203 212 10.1016/j.bbrc.2006.11.006 17113036 (Pubitemid 44821115)
30. Pharmacological reactivation of mutant p53: from protein structure to the cancer patient. Wiman KG, Oncogene 2010 29 4245 4252 10.1038/onc.2010.188 20498645
31. Selective induction of apoptosis in mutant p53 premalignant and malignant cancer cells by PRIMA-1 through the c-Jun-NH2-kinase pathway. Li Y, Mao Y, Brandt-Rauf PW, Williams AC, Fine RL, Mol Cancer Ther 2005 4 901 909 15956247 (Pubitemid 40909072)
32. Pharmacologic activation of p53 elicits Bax-dependent apoptosis in the absence of transcription. Chipuk JE, Maurer U, Green DR, Schuler M, Cancer Cell 2003 4 371 381 10.1016/S1535-6108(03)00272-1 14667504 (Pubitemid 37491098)
33. PRIMA-1(met) radiosensitizes prostate cancer cells independent of their MTp53-status. Supiot S, Zhao H, Wiman K, Hill RP, Bristow RG, Radiother Oncol 2008 86 407 411 10.1016/j.radonc.2008.01.001 18237796
34. Mutant p53 reactivation by PRIMA-1MET induces multiple signaling pathways converging on apoptosis. Lambert JM, Moshfegh A, Hainaut P, Wiman KG, Bykov VJ, Oncogene 2010 29 1329 1338 10.1038/onc.2009.425 19946333
35. XIAP regulates Akt activity and caspase-3-dependent cleavage during cisplatin-induced apoptosis in human ovarian epithelial cancer cells. Asselin E, Mills GB, Tsang BK, Cancer Res 2001 61 1862 1868 11280739 (Pubitemid 32692000)
36. AKT1/PKBalpha kinase is frequently elevated in human cancers and its constitutive activation is required for oncogenic transformation in NIH3T3 cells. Sun M, Wang G, Paciga JE, Feldman RI, Yuan ZQ, Ma XL, Am J Pathol 2001 159 431 437 10.1016/S0002-9440(10)61714-2 11485901 (Pubitemid 32751073)
37. AKT2 inhibition of cisplatin-induced JNK/p38 and Bax activation by phosphorylation of ASK1: implication of AKT2 in chemoresistance. Yuan ZQ, Feldman RI, Sussman GE, Coppola D, Nicosia SV, Cheng JQ, J Biol Chem 2003 278 23432 23440 10.1074/jbc.M302674200 12697749 (Pubitemid 36830160)
38. A phosphatidylinositol 3-kinase/Akt pathway promotes translocation of MDM2 from the cytoplasm to the nucleus. Mayo LD, Donner DB, Proc Natl Acad Sci USA 2001 98 11598 11603 10.1073/pnas.181181198 11504915 (Pubitemid 32928774)
39. Regulation of apoptosis-inducing factor-mediated, cisplatin-induced apoptosis by Akt. Yang X, Fraser M, Abedini MR, Bai T, Tsang BK, Br J Cancer 2008 98 803 808 10.1038/sj.bjc.6604223 18283299 (Pubitemid 351272611)
40. Phosphorylation of human p53 by p38 kinase coordinates N-terminal phosphorylation and apoptosis in response to UV radiation. Bulavin DV, Saito S, Hollander MC, Sakaguchi K, Anderson CW, Appella E, EMBO J 1999 18 6845 6854 10.1093/emboj/18.23.6845 10581258
41. Apoptosis induced by adenovirus-mediated p53 gene transfer in human glioma correlates with site-specific phosphorylation. Shono T, Tofilon PJ, Schaefer TS, Parikh D, Liu TJ, Lang FF, Cancer Res 2002 62 1069 1076 11861384 (Pubitemid 34160289)
42. Mutations in serines 15 and 20 of human p53 impair its apoptotic activity. Unger T, Sionov RV, Moallem E, Yee CL, Howley PM, Oren M, Oncogene 1999 18 3205 3212 10.1038/sj.onc.1202656 10359526 (Pubitemid 29286965)
43. DNA damage-induced phosphorylation of p53 alleviates inhibition by MDM2. Shieh SY, Ikeda M, Taya Y, Prives C, Cell 1997 91 325 334 10.1016/S0092-8674(00) 80416-X 9363941 (Pubitemid 27467963)